Cisapride Capsules

Animals: 1. In isolated organs, it can prevent gastric relaxation, accelerate gastric motility, and coordinate the movement of the antrum-duodenum, small intestine, and large intestine; 2. In dogs, it can enhance the digestive activity of the antrum-duodenum, coordinate and enhance gastric emptying, increase the motility of the small intestine and large intestine, and shorten the time of intestinal movement, but does not affect gastric secretion; 3. The mechanism of action is mainly to promote the physiological release of acetylcholine in the myenteric plexus; 4. It does not stimulate muscarinic and nicotinic receptors, nor does it inhibit the activity of acetylcholinesterase; 5. There is no dopamine receptor blocking effect at therapeutic doses; 1.6. It is mainly distributed in the stomach and intestinal tissues. Humans: 1 Gastrointestinal motility effects: (1) Esophagus: Enhance esophageal motility and lower esophageal sphincter tension; prevent gastric contents from reflux into the esophagus and improve esophageal clearance; (2) Stomach: Increase gastric and duodenal contractility and coordination between the antrum and duodenum; reduce duodenal-gastric reflux; improve gastric and duodenal emptying; (3) Intestines: Strengthen intestinal motility and promote transit between the small and large intestines. Other effects: br/1 Due to the lack of cholinergic effect, it does not increase basal and pentagastrin-induced gastric acid secretion; 2 Due to the relative lack of dopamine antagonist properties, it has almost no effect on plasma prolactin levels; 3 It does not affect psychomotor function, blood pressure, respiratory rate, body temperature, body weight and anticoagulation function; (4) The pharmacological effect begins 30 to 60 minutes after oral administration.

Cisapride. Chemical name: cis-4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-pyridyl]-2-methoxyaniline.

This product is a capsule, and the contents are white or off-white powder.

1. Increase gastrointestinal motility. It can be used for gastroparesis syndrome, or upper gastrointestinal discomfort, but the symptoms of X-ray and endoscopy are negative, characterized by early satiety, fullness after meals, decreased food intake, bloating, excessive belching, lack of appetite, nausea, vomiting or ulcer-like complaints (burning pain in the upper abdomen). 2. Gastroesophageal reflux, including the treatment and maintenance of esophagitis. 3. Insufficient propulsive peristalsis and gastrointestinal content retention caused by pseudo-obstruction related to motor dysfunction. 4. To restore the propulsive motility of the colon, as a long-term treatment for patients with chronic constipation.

1 Dosage: Adults: Depending on the severity of the disease, the total daily dose is 15-40 mg, divided into 2-4 doses. The following doses are usually recommended: General disease: 5 mg once, 3 times a day (the dose can be doubled); Severe disease: (gastroparesis, esophagitis, intractable constipation) 10 mg once, 3 times a day, or 10 mg once, 4 times a day, before meals and before bedtime. Or 20 mg once, 2 times a day, before breakfast and before bedtime. Maintenance treatment of esophagitis: 10 mg once, 2 times a day (before breakfast and before bedtime) or 20 mg once a day (before bedtime). For severe disease, the dose can be doubled. 2 Usage: (1) For the treatment of upper gastrointestinal disorders, it should be taken at least 15 minutes before meals and at an appropriate time before bedtime with some drinks. (2) For the treatment of constipation, the total daily dose should be taken in two doses. There are large individual differences in dosage, number of doses per day, course of treatment, and whether maintenance treatment is needed (once a day is sufficient). Although symptom improvement is often achieved within a week of treatment, ideal treatment results for patients with severe constipation may take 2 to 3 months.

1. Consistent with pharmacological activity, transient abdominal cramps, borborygmus, and diarrhea may occur. When abdominal cramps occur when taking 20 mg, the dose can be halved; when diarrhea occurs in young children or infants, the dose should be reduced as appropriate; 2. Occasionally, allergies, mild transient headaches or dizziness, and dose-related frequent urination have been reported; 3. Rare reports of reversible liver function abnormalities, with or without cholestasis. Although there have been reports of cases of gynecomastia and galactorrhea in men, the incidence (0.1%) in large-scale monitoring studies has not exceeded the common value of the general population, and all these events are reversible. The causal relationship is not clear; 4. Individual reports have reported that it affects the central nervous system, namely convulsive epilepsy, extrapyramidal reactions, and frequent urination.

1. Patients with known allergy to this product are prohibited from taking it orally or parenterally at the same time as ketoconazole, itraconazole, miconazole, fluconazole, erythromycin, clarithromycin or troleandomycin.

Precautions for children: Use with caution in children. Precautions for pregnancy and lactation: Animal reproductive toxicity and teratogenicity studies have shown that this product does not affect embryo formation, has no original embryotoxicity, and has no teratogenic effect. In a large number of population studies, cisapride does not increase fetal malformations. However, pregnant women, especially those in the first three months of pregnancy, should weigh the pros and cons. Although the amount excreted through breast milk is very small, it is still recommended that breastfeeding mothers do not use it. Precautions for the elderly: In elderly patients, due to the moderate delay in the elimination half-life of this product, the steady-state plasma concentration will generally increase, so the therapeutic dose should be reduced and used with caution.

Not yet clear.

Store in a dry place at 15℃~30℃, out of reach of children.

Calculate according to C23H29ClFN3O4 10mg

24 months

Heilongjia PROVINCE Dina Pharmacy Co., Ltd.

• Founded in:

  1998-04-10

• Address:

  Xinsheng Industrial Development Zone, Qing'an County, Heilongjiang Province

• Tax NO.:

  91231224606110140A

• Registered Funds:

  36 million yuan

• Email:

  Log in to view